712MO Final overall survival (OS) from the phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR)
| Autor: | Kurtz, J.E., Pujade-Lauraine, E., Oaknin, A., Belin, L., Grimm, C., Kocian, R., Denys, H., Rosengarten, O.S., Follana, P., Sehouli, J., Martinez-Garcia, J., Alexandre, J., Hardy-Bessard, A-C., Frenel, J-S., Sabatier, R., Gladieff, L., De La Motte Rouge, T., Lamichhane, N. Bonichon, Kalbacher, E., Heitz, F. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S546-S546 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|